Variable | Â | N (%) | M(SD) | Observed range |
---|---|---|---|---|
Total N | Â | 56 | Â | Â |
Demographics | Â | Â | Â | Â |
Female, N (%) | Â | 44 (78.6) | Â | Â |
Mean age |  |  | 53.6 (13.4) | 26–83 |
Ethnicity, N (%) | White | 35 (64.8) | Â | Â |
 | Asian | 7 (13.0) |  |  |
 | Black | 11 (20.4) |  |  |
 | Mixed | 1 (1.9) |  |  |
 | Not reported | 2 (3.8) |  |  |
Disease characteristics (baseline) | Â | Â | Â | |
Mean disease duration (Years) |  | 10.3 (9.2) | 0.2–38 | |
Experiencing comorbidity, N (%) | 32 (57.1) | Â | Â | |
Treatment type, N (%) | DMARD | 38 (67.9) | Â | Â |
 | Biologics | 14 (25.0 %) |  |  |
 | Not reported/other | 4 (7.1 %) |  |  |
Rheumatoid factor positive N (%) | 40 (71.4) | Â | Â | |
Median ESR (IQR) |  |  | 27.0 (12.0–44.0) | 2–102 |
Mean TJC |  |  | 5.2 (6.1) | 0–24 |
Mean SJC |  |  | 3.0 (2.9) | 0–10 |
Mean PGA |  |  | 45.8 (25.0) | 1–90 |
Mean DAS-28 |  |  | 4.5 (2.2) | 0.9–14.1 |
Clinical remission (DAS-28 < 2.6), N (%) | 8.0 (14.6) |  |  | |
Psychological status (baseline) | Â | Â | Â | |
Mean depression |  |  | 7.4 (4.7) | 0–20 |
Mean anxiety |  |  | 7.7 (5.0) | 0–20 |
Disease characteristics (follow-up) | Â | Â | Â | |
ESR, median (IQR) |  |  | 22.5 (8.0–44.0) | 2–114 |
TJC, M (SD) |  |  | 4.0 (5.8) | 0–28 |
SJC, M (SD) |  |  | 3.2 (3.8) | 0–16 |
PGA, M (SD) |  |  | 44.6 (26.1) | 1–100 |
DAS-28, M (SD) |  |  | 4.7 (2.8) | 0.5–17.1 |
Clinical remission (DAS-28 < 2.6), N (%) | 8.0 (16.0) |  |  |